Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

Kumar, Vivek; Chaudhary, Neha; Garg, Mohit; Floudas, Charalampos S; Soni, Parita; Chandra, Abhinav B

Kumar, Vivek; Chaudhary, Neha; Garg, Mohit; Floudas, Charalampos S; Soni, Parita; Chandra, Abhinav B.

Afiliación

Kumar V; Department of Medicine, Maimonides Medical CenterBrooklyn, NY, USA.
Chaudhary N; Department of Pediatrics, Maimonides Medical CenterBrooklyn, NY, USA.
Garg M; Department of Medicine, Maimonides Medical CenterBrooklyn, NY, USA.
Floudas CS; Department of Medicine, Maimonides Medical CenterBrooklyn, NY, USA.
Soni P; Department of Medicine, Maimonides Medical CenterBrooklyn, NY, USA.
Chandra AB; Medical Director, Yuma Regional Cancer CenterYuma, AZ, USA.

Front Pharmacol ; 8: 311, 2017.

Article en En | MEDLINE | ID: mdl-28579959

Palabras clave

check point inhibitors; immune related adverse events; ipilimumab; nivoulmab; pembrolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Front Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google